Regulation of different inflammatory diseases by Impacting the mevalonate pathway

Department of Haematology and Oncology, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
Immunology (Impact Factor: 3.8). 05/2009; 127(1):18-25. DOI: 10.1111/j.1365-2567.2008.03011.x
Source: PubMed


The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) interfere with the mevalonate pathway. While initially developed for their lipid-lowering properties, statins have been extensively investigated with respect to their impact on autoantigen and alloantigen driven immune responses. Mechanistically it was shown that statins modify immune responses on several levels, including effects on dendritic cells, endothelial cells, macrophages, B cells and T cells. Several lines of evidence suggest that statins act in a disease-specific manner and are not effective in each immune disorder. This review discusses possible modes of action of statins in modulating immunity towards autoantigens and alloantigens.

Download full-text


Available from: Lawrence Steinman, Oct 07, 2015
16 Reads
  • Source
    • "Although not specific, changes in metabolic enzymes can be critical on a mechanistic point of view. Impaired carbohydrate metabolism in schizophrenia is a good example [36] [37], as well as sterol metabolism for immune control and inflammatory diseases [38] [39]. In this frame, the added value of proteomics is both to point out the pathway of interest (and thus pharmacological entry points to modulate it) and the proteins modulated within the pathway (e. g. in [40] [41] for statins). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Proteomics will celebrate its 20th year in 2014. In this relatively short period of time, its has invaded most areas of biology and its use will probably continue to spread in the future. These two decades have seen a considerable increase in the speed and sensitivity of protein identification and characterization, even from complex samples. Indeed, what was a challenge twenty years ago is now little more than a daily routine. Although not completely over, the technological challenge now makes room to another challenge, which is the best possible appraisal and exploitation of proteomic data to draw the best possible conclusions on a biological point of view. The point developed in this paper is that proteomic data are almost always fragmentary. This means in turn that although better than a mRNA level, a protein level is often insufficient to draw a valid conclusion on a biological point of view, especially in a world where post-translational modifications play such an important role. This means in turn that transformation of proteomic data into biological data requires an important intermediate layer of functional validation, i.e. not merely the confirmation of protein abundance changes by other methods, but a functional appraisal of the biological consequences of the protein level changes highlighted by the proteomic screens. This article is protected by copyright. All rights reserved.
    Proteomics 02/2014; 14(2-3). DOI:10.1002/pmic.201300413 · 3.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A b s t r a c t Current guidelines encourage ambitious long term cholesterol lowering with statins, in order to decrease cardiovascular disease events. However, by regulating the biosynthesis of cholesterol we potentially change the form and function of every cell membrane from the head to the toe. As research into cell morphology and membrane function realises more dependencies upon cholesterol rich lipid membranes, our clinical understanding of long term inhibition of cholesterol biosynthesis is also changing. This review of non-cardiovascular research concerning such membrane effects raises important new issues concerning the clinical advantages and disadvantages of the long term use, and broadening criteria, of cholesterol reductions. K Ke ey y w wo or rd ds s: : cholesterol, exocytosis, lipid, membrane, statin.
    Archives of Medical Science 11/2008; 5(3). · 2.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We retrospectively analyzed outcomes among 567 patients with hematologic malignancies who had hematopoietic cell transplantation from human leukocyte antigen-identical sibling donors between 2001 and 2007 for a correlation between statin use and risk of graft-versus-host disease (GVHD). Compared with allografts where neither the donor nor recipient was treated with a statin at the time of transplantation (n = 464), statin use by the donor and not the recipient (n = 75) was associated with a decreased risk of grade 3-4 acute GVHD (multivariate hazard ratio, 0.28; 95% confidence interval, 0.1-0.9). Statin use by both donor and recipient (n = 12) was suggestively associated with a decreased risk of grade 3 or 4 acute GVHD (multivariate hazard ratio, 0.00; 95% confidence interval, undefined), whereas statin use by the recipient and not the donor (n = 16) did not confer GVHD protection. Risks of chronic GVHD, recurrent malignancy, nonrelapse mortality, and overall mortality were not significantly affected by donor or recipient statin exposure. Statin-associated GVHD protection was restricted to recipients with cyclosporine-based postgrafting immunosuppression and was not observed among those given tacrolimus (P = .009). These results suggest that donor statin treatment may be a promising strategy to prevent severe acute GVHD without compromising immunologic control of the underlying malignancy.
    Blood 12/2009; 115(6):1288-95. DOI:10.1182/blood-2009-08-240358 · 10.45 Impact Factor
Show more